Format
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 5

1.

Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.

Wang J, Liu Y, Li Z, Wang Z, Tan LX, Ryu MJ, Meline B, Du J, Young KH, Ranheim E, Chang Q, Zhang J.

Blood. 2011 Jul 14;118(2):368-79. doi: 10.1182/blood-2010-12-326058. Epub 2011 May 17.

2.

Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia.

Wang J, Liu Y, Li Z, Du J, Ryu MJ, Taylor PR, Fleming MD, Young KH, Pitot H, Zhang J.

Blood. 2010 Dec 23;116(26):5991-6002. doi: 10.1182/blood-2010-04-281527. Epub 2010 Oct 4.

3.

Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation.

Zhang J, Wang J, Liu Y, Sidik H, Young KH, Lodish HF, Fleming MD.

Blood. 2009 Feb 5;113(6):1304-14. doi: 10.1182/blood-2008-01-134262. Epub 2008 Dec 9.

4.

Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.

Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H, Johnson L, Akashi K, Tuveson DA, Jacks T, Gilliland DG.

J Clin Invest. 2004 Feb;113(4):528-38.

5.

Inducible gene targeting in mice.

Kühn R, Schwenk F, Aguet M, Rajewsky K.

Science. 1995 Sep 8;269(5229):1427-9.

PMID:
7660125
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk